A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
5don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback